dialysis

New York based, Keryx Biopharmaceuticals Inc., said a late-stage trial of its experimental drug, Zerenex, for kidney disease met the late-stage trial goal of reducing phosphate levels in blood. The positive results boosted Keryx shares up to 49 percent, selling for $4.80 on Monday’s Nasdaq. Because phosphate levels in blood rise when kidney function declines, […]